Teva Pharmaceutical Industries (TEVA) PT Raised to $16.00

Teva Pharmaceutical Industries (NYSE:TEVA) had its target price lifted by Mizuho from $12.00 to $16.00 in a research note released on Wednesday, MarketBeat.com reports. They currently have a neutral rating on the stock.

Several other equities research analysts have also recently commented on TEVA. Oppenheimer cut shares of Teva Pharmaceutical Industries from an outperform rating to a market perform rating and set a $41.00 price target on the stock. in a research report on Thursday, August 3rd. Credit Suisse Group set a $39.00 price target on shares of Teva Pharmaceutical Industries and gave the stock a buy rating in a research report on Thursday, August 3rd. UBS cut shares of Teva Pharmaceutical Industries from an outperform rating to a market perform rating in a research report on Thursday, August 3rd. CIBC restated a market perform rating on shares of Teva Pharmaceutical Industries in a report on Thursday, August 3rd. Finally, Vetr upgraded Teva Pharmaceutical Industries from a buy rating to a strong-buy rating and set a $34.54 price objective on the stock in a report on Thursday, August 3rd. Seven investment analysts have rated the stock with a sell rating, seventeen have given a hold rating, seven have given a buy rating and one has given a strong buy rating to the stock. Teva Pharmaceutical Industries currently has a consensus rating of Hold and an average target price of $21.65.

Shares of Teva Pharmaceutical Industries (NYSE:TEVA) opened at $15.26 on Wednesday. The company has a debt-to-equity ratio of 1.20, a current ratio of 0.96 and a quick ratio of 0.66. Teva Pharmaceutical Industries has a 1 year low of $10.85 and a 1 year high of $38.31. The company has a market cap of $15,057.12, a PE ratio of 3.42 and a beta of 0.55.

The firm also recently announced a quarterly dividend, which will be paid on Tuesday, December 12th. Shareholders of record on Tuesday, November 28th will be paid a dividend of $0.085 per share. The ex-dividend date of this dividend is Monday, November 27th. This represents a $0.34 annualized dividend and a yield of 2.23%. Teva Pharmaceutical Industries’s dividend payout ratio (DPR) is presently -16.97%.

A number of large investors have recently added to or reduced their stakes in the business. San Francisco Sentry Investment Group CA bought a new stake in shares of Teva Pharmaceutical Industries in the 2nd quarter valued at approximately $106,000. Kistler Tiffany Companies LLC grew its stake in shares of Teva Pharmaceutical Industries by 74.7% in the 2nd quarter. Kistler Tiffany Companies LLC now owns 3,673 shares of the company’s stock valued at $122,000 after buying an additional 1,571 shares in the last quarter. Bronfman E.L. Rothschild L.P. grew its stake in shares of Teva Pharmaceutical Industries by 2.6% in the 2nd quarter. Bronfman E.L. Rothschild L.P. now owns 3,711 shares of the company’s stock valued at $123,000 after buying an additional 94 shares in the last quarter. Penserra Capital Management LLC bought a new stake in shares of Teva Pharmaceutical Industries in the 3rd quarter valued at approximately $129,000. Finally, Shelter Mutual Insurance Co bought a new stake in shares of Teva Pharmaceutical Industries in the 2nd quarter valued at approximately $133,000. 52.05% of the stock is currently owned by institutional investors.

WARNING: This article was first posted by Transcript Daily and is owned by of Transcript Daily. If you are reading this article on another publication, it was stolen and reposted in violation of US & international copyright and trademark laws. The original version of this article can be accessed at https://transcriptdaily.com/2017/12/03/teva-pharmaceutical-industries-teva-pt-raised-to-16-00.html.

Teva Pharmaceutical Industries Company Profile

Teva Pharmaceutical Industries Limited is a pharmaceutical company. The Company is engaged in developing, producing and marketing generic medicines and a portfolio of specialty medicines. The Company operates through two segments: Generic medicines and Specialty medicines. The Company develops, manufactures and sells generic medicines in a range of dosage forms, including tablets, capsules, injectables, inhalants, liquids, ointments and creams.

Analyst Recommendations for Teva Pharmaceutical Industries (NYSE:TEVA)

Receive News & Ratings for Teva Pharmaceutical Industries Limited Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Teva Pharmaceutical Industries Limited and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply